Topological localization of plasminogen activator inhibitor type 2

Cytometry

Volumn 40, Issue 1, 2000, Pages 32-41

  Liew, Michael A ^a   McPhun, Virginia ^b   Baker, Mark S ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b Biology and Environment   (Australia)

Author keywords

Cell surface; Leukocytes; Plasma membrane; Urokinase

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL LINE; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CELL MEMBRANE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; MONOCYTES; PLASMINOGEN ACTIVATOR INHIBITOR 2; U937 CELLS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034193180     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(20000501)40:1<32::AID-CYTO5>3.0.CO;2-Z     Document Type: Article

References (48)

1. Baker MS, Bleakley P, Woodrow GC, Doe WF. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 1990;50:4676-4684.
2. Baker MS, Hornby J, Woodrow G, Maxwell L, McPhun V. A novel monoclonal antibody which specifically recognises the formation and fate of cellular uPA:PAI-2 complexes. Cold Springs Harbour Meeting. Cold Springs Harbor; 1993.
3. Belin D. Biology and facultative secretion of plasminogen activator inhibitor-2. Thromb Haemost 1993;70:144-147.
4. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398-405.
5. Boukamp P, Petrussevska RT, Breitzkreuz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988;106:761-771.
6. Brunette DM, Till JE. A rapid method for the isolation of L-cell surface membranes using an aqueous two-phase polymer system. J Membr Biol 1971;5:215-224.
7. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
8. Dear AE, Medcalf RL. The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 1995;9:321-330.
9. 3: synergistic effects on tissue transglutaminase. Leukemia 1995;9:1762-1767.
10. Dickinson JL, Bates EW, Ferrante A, Antalis T. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 1995; 270:27894-27904.
11. Felez J, Chanquia CJ, Levin EG, Miles LA, Plow EF. Binding of tissue plasminogen activator to human monocytes and monocytoid cells. Blood 1991;78:2318-2327.
12. Felez J, Chanquia CJ, Fabregas P, Miles LA, Plow EF. Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood 1993;82: 2433-2441.
13. Frankenberger M, Pforte A, Sternsdorf T, Passlick B, Baeuerle PA, Ziegler-Heitbrock HW. Constitutive nuclear NF-kappa B in cells of the monocyte lineage. Biochem J 1994;304:87-94.
14. Gilabert J, Estelles A, Ayuso MJ, España F, Chirivella M, Grancha S, Mico JM, Aznar J. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation. Gynecol Obstet Invest 1994;38:157-162.
15. Gross TJ, Sitrin RG. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2. J Immunol 1990;144:1873-1879.
16. Hayashi S, Okabe-Kado J, Honma Y, Kawajiri K. Expression of Ah receptor (TCDD receptor) during human monocytic differentiation. Carcinogenesis 1995;16:1403-1409.
17. Jensen PH, Nykjaer A, Andreasen PA, Lund LR, Astedt B, Lecander I. Urokinase binds to a plasminogen activator inhibitor type-2 like molecule in placental microvillus membranes. Biochim Biophys Acta 1989;986:135-140.
18. Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type 2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminasecatalyzed cross-linking to cellular and extracellular structures. Eur J Biochem 1993;214:141-146.
19. Jensen PH, Cressey LI, Gjertsen BT, Madsen P, Mellgren G, Hokland P, Gliemann J, Døskland SO, Lanotte M, Vintermyr OK. Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis. Br J Cancer 1994;75:834-840.
20. Jensen PJ, Wu Q, Janowitz PJ, Ando Y, Schechter NM. Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp Cell Res 1995;217:65-71.
21. Kawano T, Morimoto K, Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J Biochem 1970;67:333-342.
22. Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, Vanky F. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 1976;18:421-431.
23. Kradin RL, Lynch GW, Kurnick JT, Erikson M, Colvin RB, McDonagh J. Factor XIII A is synthesized and expressed on the surface of U937 cells and aveolar macrophages. Blood 1987;69:778-785.
24. Kruithof EKO, Vassalli JD, Schleuning W-D, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U937. J Biol Chem 1986;261:11207-11213.
25. Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987;69:460-466.
26. Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995;86:4007-4024.
27. Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type 2. J Biol Chem 1991;256:20960-20964.
28. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EKO. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993;55:6051-6057.
29. Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M, Jensen PJ. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochem J 1994;101:105-112.
30. Mehta K, Lopez-Berestein G, Moore WT, Davies PJA. Interferon γ requires serum retinoids to promote the expression of tissue transglutaminase in cultured human blood monocytes. J Immunol 1985; 134:2053-2056.
31. Moller LB. Structure and function of the urokinase receptor. Blood Coagul Fibrinolysis 1993;4:293-303.
32. Oliver LJ, Keelon M, Wilson EL. Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562). Blood 1989;74:1.321-1327.
33. Plow EF, Miles LA. Plasminogen receptors in the mediation of pericellular proteolysis. Cell Differ Dev 1990;32:293-298.
34. Plow EF, Felez J, Miles LA. Cellular regulation of fibrinolysis. Thromb Haemost 1991;66:32-36.
35. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995;9:939-945.
36. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57:273-328.
37. Rana AP, Majumder GC. Factors influencing the yield and purity of goat sperm plasma membrane isolated by means of an aqueous two-phase polymer system. Prep Biochem 1987;17:261-281.
38. Rehemtulla A, Arndt A, Hart DA. Induction of plasminogen activator inhibitor type 2 expression during differentiation of human K562 cells towards a macrophage phenotype. Biochem Cell Biol 1990;68: 1337-1343.
39. Reinartz J, Schaefer B, Bechtel MJ, Kramer MD. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Exp Cell Res 1996;223:91-101.
40. Reiter LS, Spertini O, Kruithof EKO. Plasminogen activators play an essential role in extracellular-matrix invasion by lymphoblastic T-cells. Int J Cancer 1997;70:461-466.
41. Schuster WA, Medcalf RL, Kruithof EKO. Retinoic acid potentiates phorbol ester-mediated induction of urokinase and plasminogen activator inhibitor type 2 in human mycloid leukemic cell lines. Endocrinology 1993;133:1724-1730.
42. Stephens RW, Golder JP. Novel properties of human monocyte plasminogen activator. Eur J Biochem 1984;139:253-258.
43. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980;26:171-176.
44. Vassalli JD, Sappino AP, Belin D. The plasminogen activaior/plasmin system. J Clin Invest 1991;88:1067-1072.
45. Vassalli J-D, Wohlwend A, Belin D. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localised and regulated proteolytic system. Curr Top Microbiol Immunol 1992;181: 65-86.
46. Wohlwend A, Belin D, Vassalli J-D. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 1987;165:320-339.
47. Xie M, Low MG. Expression and secretion of glycosylphosphatidylinositol-specific phospholipase D by myeloid cell lines. Biochem J 1994;297:547-554.
48. Ziegler-Heitbrock HW, Thiel E, Futterer A, Herzgog V, Wirtz A, Reithmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytcs. Int J Cancer 1988;41:-456-461.